Preliminary clinical data from a Moffitt-sponsored trial of tumor infiltrating lymphocyte therapy in lung cancer has little read-across to Iovance Biotherapeutics’ TIL platform, B. Riley FBR analyst Madhu Kumar tells investors in a research note. He reiterates a Buy rating on Iovance with a $24 price target. The stock in morning trading is down 13%, or $2.25, to $14.70.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.